Huntingdon Life Sciences and Harlan Laboratories announce new equity funding

The combined company, soon to be called Envigo, has received a commitment of up to $125 million in minority equity financing.

Huntingdon (UK), 17th July, 2015: Huntingdon Life Sciences (HLS) and Harlan Laboratories, soon to be called Envigo, is pleased to announce that a group of institutional investors has committed up to $125 million in a minority equity financing that can be used to fund future growth initiatives.

Brian Cass, CEO, commented: "We recently announced our rebranding of the Company to Envigo as we complete the integration of HLS and Harlan to broaden the support we provide to life science research. This equity investment of up to $125 million validates the success of that integration and further strengthens the Company's balance sheet to pursue additional organic and strategic investments.  We look forward to leveraging the resources of the investor group as we continue to grow Envigo and enhance our market leading position."

The new Company is a leading provider of non-clinical contract research, research models, products and services to the pharmaceutical, crop protection and chemical industries, universities, government, and other research organizations.  At the official launch of Envigo in a few months' time the Company will have 3,800 employees and revenue of approximately $500 million. It will be the largest provider of research services to the crop protection and chemical industries, the second largest supplier of research models and services, and the third largest provider of preclinical research services to the pharmaceutical industry. 

-ENDS-

Notes to editors

About Huntingdon Life Sciences

Huntingdon Life Sciences is a privately held global provider of essential non-clinical contract research services to the pharmaceutical, crop protection and chemical industries. www.huntingdon.com

About Harlan Laboratories

Harlan Laboratories, Inc. is a leading provider of non-clinical contract research, research models and services, and animal diets and products, to the pharmaceutical, biotech, medical device, crop protection and chemical industries, universities, government, and other research organizations. www.harlan.com

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on +44 (0) 203 735 8166 or +44 (0) 203 735 8165 or e-mail: [email protected].

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.